Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc.

108 F. Supp. 2d 125, 2000 U.S. Dist. LEXIS 14613, 2000 WL 840048
CourtDistrict Court, D. Connecticut
DecidedMarch 31, 2000
Docket3:97CV1795 AVC
StatusPublished

This text of 108 F. Supp. 2d 125 (Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc., 108 F. Supp. 2d 125, 2000 U.S. Dist. LEXIS 14613, 2000 WL 840048 (D. Conn. 2000).

Opinion

RULING ON THE PLAINTIFFS’ MOTION FOR FINAL ORDER OF JUDGMENT PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 54(b)

COVELLO, District Judge.

This is a consolidated action for legal and equitable relief in which the plaintiffs, thirty-seven health care insurers, four health care plans, and six individuals, claim that the defendant, SmithKline Beecham Clinical Laboratories, Inc. (SBCL), engaged in, inter alia, fraudulent billing practices. The second amended complaint and the amended class action complaint assert causes of action under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1961 et seq. (“RICO”), the Employee Retirement Income Security Act, 29 U.S.C. § 1001 et seq. (“ERISA”), the Pennsylvania Insurance Fraud Statute, 18 Pa.Stat.Ann. § 4117(a)(2) and under state common law tenets sounding in unjust enrichment and restitution.

On July 2, 1999, this court dismissed the RICO action asserted in counts I, II and III of the second amended class action complaint, the ERISA action asserted in count IV of the second amended class action complaint to the extent the claims were asserted by 31 of the plaintiff-insurers, and count V alleging federal common law claims. Further, the court dismissed counts I and III of the consolidated class action complaint alleging causes of action under RICO and federal common law, respectively, and dismissed counts IV, V and VI of the consolidated class action complaint to the extent those claims were asserted by four plaintiffs-employee benefit plans.

The plaintiffs make the within motion pursuant to Rule 54(b) of the Federal Rules of Civil Procedure. 1 The issue presented is whether entry of final judgment is appropriate as to Counts I, II, III and IV. For the reasons hereinafter set forth, the plaintiffs’ motion for final judgment (document no. 222), is GRANTED.

FACTS

On August 19, 1997, thirty-seven insurance companies initiated this lawsuit.

On June 11, 1998, the court dismissed the plaintiff insurers’ amended complaint and the individual plaintiffs (now the “class plaintiffs”) complaint, but gave them leave to re-file their claims against SBCL.

*127 On September 18, 1998, the plaintiff insurers filed their second amended complaint against SBCL.

On September 29, 1998, the “class plaintiffs” 2 filed their consolidated amended class action complaint.

The second amended complaint and the amended class action complaint disclose that the plaintiff insurers are thirty-seven health insurers 3 and payers for health care services, and 'the “class plaintiffs” 4 are four employer benefit plans, one corporation 5 and six individuals. SBCL is a subsidiary of SmithKline Beecham pic, a British corporation and incorporated in the state of Delaware. SBCL owns and operates one of the nation’s largest chains of clinical laboratories.

The gravamen of the second amended complaint and the RICO Case Statement is that from 1989 until 1995, SBCL engaged in fraudulent billing practices that resulted in millions of dollars in losses to the plaintiff insurers. Specifically, the plaintiff insurers allege that SBCL exploited the health care payment system in five fundamental ways: 1) SBCL billed the plaintiff insurers for tests that physicians did not order or intend to order and billed for tests that it had led physicians to believe would not result in separate charges (“add-ons”); 2) SBCL offered physicians discounts for certain test packages, but billed the plaintiff insurers for the full price for supposedly discounted test packages (“selective discounts”); 3) SBCL billed the plaintiff insurers separately for expensive constituents of test panels that should have been billed at a single composite rate (“unbundling”); 4) SBCL performed and billed for more expensive tests *128 than were ordered (“upcoding”), and in some cases performed; and 5) SBCL inserted fabricated diagnosis codes to obtain reimbursement from third-party payers (“code jamming”).

The plaintiff insurers allege that through this scheme, SBCL effectively substituted its own financially self-interested judgment for the informed, clinical judgment of physicians. The plaintiff insurers further allege that SBCL forced its scheme upon unsuspecting physicians by offering institutional incentives and kickbacks. The incentives included test discounts, hiring physician family members, computer equipment, refrigerators, free phlebotomists’ services, office draw sites and other free services, such as writing off STAT (urgent) services which were then billed to third-party payers.

The amended class action complaint alleges that between 1989 and 1995, SBCL engaged in fraudulent billing practices, causing the class plaintiffs to pay inflated charges for clinical laboratory tests. The class plaintiffs claim that “SBCL used its control over the management of the Laboratory Network to engage in a fraudulent scheme with respect to clinical laboratory tests on human tissue, blood or urine specimens, which resulted in the intentional and — systematic:” 1) billing, for medical tests that physicians did not order or intend to order; 2) billing for medical tests that SBCL had intentionally led doctors to believe would not result in additional charges (“add-ons”); 8) billing at full price, for tests that SBCL had represented would be discounted (“selective discounts”); 4) manipulation of the test requisition order forms provided to physicians by SBCL; 5) billing separately for individual test panels, thereby dramatically increasing the cost (“unbundling”); and 6) altering of physician orders for standard tests so that the more expensive medical tests were conducted and paid for by the class plaintiffs (“upcoding”).

On November 17, 1998, SBCL filed motions to dismiss the second amended complaint and to dismiss counts I and III of the consolidated amended class action complaint, as well as counts IV, V, and VI of the consolidated class action complaint, to the extent those claims are asserted by the four employee benefit plans defined therein.

On July 2, 1999, the court, inter alia, dismissed the plaintiff insurers RICO causes of action, Counts I, II and III. In addition, the court dismissed Count IV with respect to 31 plaintiff insurers. (See n. 1 for the 31 plaintiff insurers.)

STANDARD

Rule 54(b) of the Federal Rules of Civil Procedure

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sears, Roebuck & Co. v. MacKey
351 U.S. 427 (Supreme Court, 1956)
Curtiss-Wright Corp. v. General Electric Co.
446 U.S. 1 (Supreme Court, 1980)
Reiter v. Cooper
507 U.S. 258 (Supreme Court, 1993)
Roebuck v. Guttman
678 F. Supp. 68 (S.D. New York, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
108 F. Supp. 2d 125, 2000 U.S. Dist. LEXIS 14613, 2000 WL 840048, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blue-cross-of-california-v-smithkline-beecham-clinical-laboratories-inc-ctd-2000.